[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578334":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 15 mg","EXPERIMENTAL",null,[13],"Drug: injection with 15 mg bevacizumab-800CW before bronchoscopy",{"label":15,"type":10,"description":11,"interventionNames":16},"Fluorescence molecular imaging during bronchoscopy with bevacizumab-800CW at dose of 25 mg",[17],"Drug: injection with 25 mg bevacizumab-800CW before bronchoscopy",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","injection with 15 mg bevacizumab-800CW before bronchoscopy","Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.",[9],{"type":20,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"injection with 25 mg bevacizumab-800CW before bronchoscopy",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Frederike Bensch, MD, PhD","CONTACT","0031503610280","f.bensch@umcg.nl",[34],{"facility":5,"status":11,"city":35,"state":11,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Groningen","Netherlands","NL",{"type":39,"coordinates":40},"Point",[41,42],6.56667,53.21917,{"lat":42,"lon":41},[45],{"name":29,"role":30,"phone":11,"phoneExt":11,"email":32},{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100578334","phase-2-feasibility-of-fluorescence-imaging-with-bevacizumab-800cw-during-bronchoscopy-100578334",false,"NCT06809946","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy","Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I","DEFLECT I","Inclusion Criteria:\n\n1. Signed informed consent prior to participation in the study.\n2. Age ≥ 18 years.\n3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).\n4. Patient is considered fit to undergo a diagnostic and\u002For therapeutic bronchoscopy (with or without addition of virtual navigation and\u002For endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.\n\nExclusion Criteria:\n\n1. History of infusion reactions to bevacizumab.\n2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.\n3. Pregnancy or breast feeding.","ALL","18 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and\u002For lymph nodes considered to be malignant.",[66,67,68,69],"Lung Neoplasms","Pulmonary Neoplasms","Lymph Node Involvement","Pulmonary Nodule",[71,72,73,74,75],"Fluorescence molecular bronchoscopy","Bevacizumab-800CW","Near-infrared fluorescence imaging","Molecular imaging","Pulmonary nodule","NOT_YET_RECRUITING","2026-03-24",{"date":79,"type":80},"2026-03-30","ACTUAL",{"date":82,"type":60},"2026-08-17",{"date":84,"type":60},"2028-08-17",{"name":5,"class":6},1]